Most of what makes cannabis medicine contentious is a long-term worry. Dependence over years, psychosis risk in the young, what a decade of daily THC does to memory. In hospice those arguments carry the least weight they carry anywhere, and comfort carries the most. That changes the question. The useful test is narrower than whether cannabis beat placebo in a trial: does it help this person this week, and does it sit safely next to everything the hospice is already giving?
Our view is that a hospice patient who wants to try cannabis has a better case than almost any other patient on this site, and that the case rests on comfort and the patient's own choice, since the trials in advanced illness mostly came back flat. Two things decide whether it goes well. The hospice team has to know, since the sedation adds to what they are already managing. And an edible has to be swallowed, which in the last days of life is often the one thing the person can no longer do.
Does cannabis help hospice patients?
Not measurably, in the controlled trials. A 2018 meta-analysis of nine studies and 1,561 palliative patients found no significant difference from placebo in cancer patients for appetite, calorie intake, nausea, pain or sleep. Two Australian trials since then, one of CBD and one of 1:1 THC and CBD, also did no better than placebo on total symptom burden.
The Australian work is the closest thing the field has to hospice-grade evidence, because Janet Hardy's Brisbane group enrolled people already under specialist palliative care. In the CBD trial (published in the Journal of Clinical Oncology in 2023 and covered in detail on our cancer-related anxiety page), patients titrated themselves to a median 400mg of CBD a day. Symptom distress improved in both arms, and slightly more on placebo: 58.7% of the placebo group met the response mark against 44.8% on CBD. The authors' conclusion was that CBD added nothing to what palliative care was already doing.
The THC trial reported in 2025 is the more useful one for anyone holding a gummy. Patients settled on a median 1.5ml of a 10mg/ml oil, or 15mg of THC and 15mg of CBD a day, which lands at the top of the moderate tier in our dosing guide (5 to 15mg). Total symptom scores fell by almost exactly the same amount in both arms. Pain scores did fall further on cannabis (1.42 points against 0.46), and the price was visible in the side-effect table:
- Confusion: 37.7% on cannabis, 16.7% on placebo
- Feeling high: 29.0% against 13.9%
- Serious adverse events: 10 in the cannabis arm, 3 on placebo
- General well-being: better on placebo at day 14
Pain relief is the one signal, and our cancer pain page works through it. Nausea from chemotherapy is a different story with better trials, on the chemotherapy nausea page. Outside cancer the cupboard is barer still. In advanced COPD, a McGill trial gave 16 patients a single dose of vaporized high-THC cannabis and found no effect on breathlessness or exercise endurance compared with a near-placebo strain.
Why does the hospice setting change the question?
Because time is short and the goal is comfort. MedPAC reports that the median Medicare hospice patient who died in 2024 had 19 days of hospice care. Over that horizon, the harms that dominate cannabis debates (dependence, years of cognitive effects) barely register, and whether the person feels better tonight matters most.
There is a mild absurdity in the arithmetic. Both Brisbane trials ran 28 days, which is longer than the median hospice stay, so the evidence everyone cites was measured over a stretch most hospice patients do not get. A trial can tell you that, averaged across a hundred people, the oil did no better than placebo. It cannot tell a daughter whether her father, who liked a joint in 1974 and asks for one now, will sleep better on it.
The median hides a split by diagnosis, though, and it matters for this page because hospice is far from a cancer-only service. MedPAC's same report puts the average lifetime stay at 51 days for cancer, 133 days for COPD and 169 days for neurological conditions. Someone on hospice for half a year faces months of falls risk, confusion and drug interactions, and the long-term arguments start to count again. Our pages on Alzheimer's agitation and ALS cover those diagnoses on their own evidence.
Will the hospice provide cannabis or allow the patient's own?
Each hospice sets its own policy, and no published count says how many allow what. Hospice runs largely on federal money, which the authors of a 2019 survey of 310 hospice professionals gave as the reason programs are unsure how to handle cannabis requests. Respondents overwhelmingly backed patient access. Ask the hospice for its written policy.
The rules behind that survey have shifted since. The April 28, 2026 rescheduling order moved state-licensed medical marijuana into Schedule III, and our legal explainer tracks where that stands. None of the published hospice policy research postdates it, so nobody has measured whether hospice formularies changed in response.
The professional line comes from the Hospice and Palliative Nurses Association, whose December 2020 position statement asks nurses to ask every patient about cannabis and record the answer as part of medication reconciliation. It says patients should be offered FDA-approved medicines first and that a patient's preference for cannabis should be considered in the treatment plan, with any use held to the same standards as other medicines, informed consent included. It also tells nurses not to recommend CBD products until high-quality research shows they are safe and effective, and flags cost, noting that some families spend heavily on products they believe are cures.
At least one hospice has gone further than allowing. A Connecticut inpatient hospice gave 66 patients on scheduled opioids a standardized oral product (40mg CBD with 1.5mg THC, or 80mg with 3mg) and reported lower pain scores over 996 treatment days, with minor reversible side effects possibly related to cannabis in three patients and no serious ones. There was no placebo arm, so the study shows a hospice can give cannabis alongside scheduled opioids and says little about whether it worked.
One survey points the other way. Of 342 terminally ill Illinois medical cannabis patients surveyed, 323 were planning to enroll in hospice and only 19 had. The authors worried that cannabis was operating as a substitute for hospice and palliative care. A gummy cannot replace a nurse who answers the phone at 3 a.m.
What happens when cannabis meets the medicines hospice already gives?
The sedation adds up. The FDA label for dronabinol, prescription THC, warns of additive central nervous system depression with benzodiazepines and barbiturates, and names opioids, antihistamines, anticholinergics and muscle relaxants among the drugs that add to its drowsiness and confusion. Most hospice medication lists include several of those.
The label also says elderly patients are more sensitive to THC's neuropsychiatric effects and to the drop in blood pressure on standing, that people with dementia face a higher fall risk, and that people with heart problems face a higher risk of blood pressure changes. That last line covers every hospice patient admitted with heart failure.
An edible makes all of this harder to read. Onset runs 30 minutes to 2 hours after eating, with the peak 2 to 3 hours in, per our edible timing guide. A gummy at 8 p.m. can land on top of the 10 p.m. lorazepam, and new confusion at midnight looks the same whether it came from the cannabis, the morphine, an infection or the illness itself. The confusion rate in the Brisbane THC arm (more than double placebo) is a reminder that the drug can cause the very symptom the family is watching for. The hospice nurse and physician manage symptom changes, so they need to know what went in and when.
What if the patient can no longer swallow?
An edible is then off the table, and that tends to happen in the final week. In a study of 357 cancer patients in palliative care units in Houston and Brazil, trouble swallowing liquids appeared a median of 7 days before death and was present in most of those who died by 12 hours before the end. Whether anything goes by mouth is the hospice nurse's call.
The same research group documented a second problem. Over the last seven days of life, the share of patients able to communicate fell from 80% to 39%. A comfort measure the patient chose needs the patient to say whether it is helping, and in the last days that report often stops coming. Families who keep giving a gummy because "he wanted it" are deciding on his behalf, and the HPNA's informed-consent standard applies to that decision too. Where a person can no longer decide, the formal surrogate process the long-term care medicine society AMDA describes, set out on our appetite loss page, is the model, with the hospice physician involved. Appetite itself is the other common request, and the meta-analysis above found cannabinoids no better than placebo for it in cancer, which our cachexia page covers.